Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The heavy disease burden is mainly due to diabetic complications. Diabetes is a major risk factor for cardiovascular disease (CVD) and chronic kidney disease (CKD).China has been the largest absolute disease burden of diabetes in the world recently1. Diabetic patients with established CVD or CKD are bringing growing pressure upon our nation's healthcare expenditure1. However, the characteristic profile of Chinese diabetic patients who has CVD, CKD or at high risk of CVD remains unclear thus is in urgent need for in-depth investigation.In current China, however, the information regarding diabetes or non-diabetes patients who also had other comorbid conditions (e.g. established CV diseases, CKD or at high risk for such problem), is limited; the patient characteristics, treatment patterns and economic burden may not be fully understood.Therefore, based on TianJin regional database, the investigators will describe the demographic, clinical characteristics, treatment, and economic burden of disease of Chinese diabetic/non-diabetic patients with/without established CV disease, CKD, or at high CV risk including hypertension and hyperlipidaemia. And the investigators believe that the resulting findings will inform a comprehensive group of evidence users to achieve better healthcare for diabetes patients with established or at high risk of CVD or CKD.
The study aimed to investigate the clinical characteristics, treatment, and economic burden of disease of Chinese diabetic/non-diabetic patients with/without established cardiovascular disease, chronic kidney disease, or at high cardiovascular risk, including:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Diabetic patients with CVD, CKD or at risk | The group A include all diabetic patients with established cardiovascular disease, chronic kidney disease, or at high cardiovascular risk. | ||
| Diabetic patients without CVD, CKD or at risk | The group B include all diabetic patients without established cardiovascular disease, chronic kidney disease, or at high cardiovascular risk. | ||
| Non-diabetic patients with CVD, CKD or at risk | The group C included all non-diabetic patients with established cardiovascular disease, chronic kidney disease, or at high cardiovascular risk. | ||
| Health controls | The group D included non-diabetic patients without established cardiovascular disease, chronic kidney disease, and not at high cardiovascular risk. |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| The number of diabetic/non-diabetic patients with disease or risk | The number of diabetic patients with established cardiovascular disease, chronic kidney disease, or at high cardiovascular risk among all patients with diabetes; | 10 months after enrollment |
| The proportion of diabetic/non-diabetic patients with disease or risk | The proportion of diabetic/non-diabetic patients with established cardiovascular disease, chronic kidney disease, or at high cardiovascular risk among patients without diabetes | 10 months after enrollment |
| The demographic characteristics of the last visit for all patients of the studied population |
| 10 months after enrollment |
| The diagnosis of patients | The number of patients with diagnosis at the last visit | 10 months after enrollment |
| The proportion of death | The proportion of death at the last visit; the proportion of death at admission of the last visit for inpatients in 2008, 2013 and 2018. | 10 months after enrollment |
| Random blood glucose (mmol/L) | The most recent value of random blood glucose (mmol/L) within the previous year for outpatients; the value of random blood glucose (mmol/L) at admission of the last visit for inpatients in 2008, 2013, 2018. | 12 months after enrollment |
| HbA1C (%) |
| Measure | Description | Time Frame |
|---|---|---|
| The number of patients with different treatment pattern |
We descirbe the treatment pattern based on treatment prescribed during the most recent visit for all inpatients, and based on at least 2 prescription within the previous year for outpatients |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Diabetic/non-diabetic patients with/without established cardiovascular disease, chronic kidney disease, or at high cardiovascular risk in TianJin regional database
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Xin Sun, PhD | The West China Hospital of Sichuan university | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Tian Jin Healthcare Big Data Co. Ltd | Tianjin | Tianjin Municipality | 300000 | China |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D018376 | Cardiovascular Abnormalities |
| D051436 | Renal Insufficiency, Chronic |
| D003920 | Diabetes Mellitus |
| ID | Term |
|---|---|
| D002318 | Cardiovascular Diseases |
| D000013 | Congenital Abnormalities |
| D009358 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities |
| D051437 | Renal Insufficiency |
Not provided
Not provided
Not provided
Not provided
Not provided
The most recent value of HbA1C (%) within the previous year for outpatients; the value of HbA1C (%) at admission of the last visit for inpatients in 2008, 2013, 2018. |
| 12 months after enrollment |
| Department of discharge for hospitalized patients | Department of discharge of the last visit for hospitalized patients; and summarize the number of patients of different department of discharge in 2008, 2013, 2018. | 12 months after enrollment |
| serum creatinine (μmol/L) | The most recent value of serum creatinine (μmol/L) within the previous year for outpatients; the value of serum creatinine (μmol/L) at admission of the last visit for inpatients in 2008, 2013, 2018. | 12 months after enrollment |
| eGFR (mL/min/1.73m2) | The most recent value of eGFR (mL/min/1.73m2) within the previous year for outpatients; the value of eGFR (mL/min/1.73m2) at admission of the last visit for inpatients in 2008, 2013, 2018. | 12 months after enrollment |
| Microalbuminuria (MALB) (mg/24h) | The most recent value of microalbuminuria (MALB, mg/24h) within the previous year for outpatients; the value of microalbuminuria (MALB, mg/24h) at admission of the last visit for inpatients in 2008, 2013, 2018. | 12 months after enrollment |
| High density lipoprotein (HDL) (mmol/L) | The lasted examination of high density lipoprotein (HDL) (mmol/L) within the last year for outpatients; the value of high density lipoprotein (HDL) (mmol/L) at admission of the last visit for inpatients in 2008, 2013, 2018. | 12 months after enrollment |
| Low density lipoprotein (LDL) (mmol/L) | The lasted examination of low density lipoprotein (HDL) (mmol/L) within the last year for outpatients; the value of low density lipoprotein (HDL) (mmol/L) at admission of the last visit for inpatients in 2008, 2013, 2018. | 12 months after enrollment |
| Total cholesterol (TC) (mmol/L) | The lasted examination of total cholesterol (TC) (mmol/L) within the last year for outpatients; the value of total cholesterol (TC) (mmol/L) at admission of the last visit for inpatients in 2008, 2013, 2018. | 12 months after enrollment |
| Triglyceride (TG) (mmol/L) | The lasted examination of triglyceride (TG) (mmol/L) within the last year for outpatients; the value of triglyceride (TG) (mmol/L) at admission of the last visit for inpatients in 2008, 2013, 2018. | 12 months after enrollment |
| 10 months after enrollment |
| The length of stay in the hospital | describe the length of stay in the hospital of the last hospitalization, the length stay in the hospital for inpatients from 2008 to 2018. | 12 months after enrollment |
| The economic burden | hospitalization cost of the studied population for the last visit; total cost and hospitalization cost of the studied population from 2008 to 2018. | 12 months after enrollment |
| Numbers of admissions | The total number of admissions for inpatients from 2008 to 2018 | 12 months after enrollment |
| The proportion of re-hospitalization | The last visiting and previous one within 30 days and 90 days | 12 months after enrollment |
| D007674 | Kidney Diseases |
| D014570 | Urologic Diseases |
| D052776 | Female Urogenital Diseases |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
| D052801 | Male Urogenital Diseases |
| D002908 | Chronic Disease |
| D020969 | Disease Attributes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D044882 | Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
| D004700 | Endocrine System Diseases |